Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin.

Takeshi KawakamiAkiko TodakaKotoe OshimaKunihiro FushikiSatoshi HamauchiTakahiro TsushimaTomoya YokotaYusuke OnozawaHirofumi YasuiKentaro Yamazaki

Published in: BMC cancer (2023)

Nanoliposomal irinotecan was efficacious and tolerable in clinical practice. GPS and CA19-9 response were good candidates as predictive biomarkers, whereas GPS was a good candidate prognostic biomarker for the nanoliposomal irinotecan plus 5-FU/LV regimen.

Keyphrases

clinical practice
protein kinase